FDA Approves J&J’s Icotyde Pill as TrumpRx Pricing Falls Short
Roughly one-third of the 54 medicines listed on TrumpRx are priced lower in the UK than on the U.S. website, undermining expectations for cash-price ceilings on J&J and peers. The FDA has approved J&J’s once-daily IL-23 inhibitor Icotyde for plaque psoriasis, positioning it against rival injectables Tremfya and Skyrizi.
1. TrumpRx Pricing Analysis
The TrumpRx site sets a cash-price ceiling by listing 54 medicines at targeted international rates but a price comparison reveals that roughly one-third are cheaper in the UK than in the U.S., calling into question its impact on J&J’s pricing power.
2. FDA Approval of Icotyde
The FDA has approved Icotyde, J&J’s once-daily oral IL-23 inhibitor for moderate-to-severe plaque psoriasis, offering a pill alternative to leading injectables Tremfya and Skyrizi and expanding J&J’s dermatology portfolio.